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Reduced Cardioprotective Action of Adiponectin
in High-Fat Diet–Induced Type II Diabetic Mice
and Its Underlying Mechanisms
Wei Yi,1,2,* Yang Sun,1,3,* Erhe Gao,4 Xufeng Wei,1,2 Wayne Bond Lau,1 Qijun Zheng,1,2 Yajing Wang,1
Yuexing Yuan,1 Xiaoliang Wang,1 Ling Tao,5 Rong Li,6 Walter Koch,2 and Xin-Liang Ma1

Abstract

Diabetes exacerbates ischemic heart disease morbidity and mortality via incompletely understood mechanisms.
Although adiponectin (APN) reduces myocardial ischemia/reperfusion (MI/R) injury in nondiabetic animals,
whether APN’s cardioprotective actions are altered in diabetes, a pathologic condition with endogenously
reduced APN, has never been investigated. High-fat diet (HD)–induced diabetic mice and normal diet (ND)
controls were subjected to MI via coronary artery ligation, and given vehicle or APN globular domain (gAPN,
2 mg/g) 10 min before reperfusion. Compared to ND mice (where gAPN exerted pronounced cardioprotection),
HD mice manifested greater MI/R injury, and a tripled gAPN dose was requisite to achieve cardioprotective
extent seen in ND mice (i.e., infarct size, apoptosis, and cardiac function). APN reduces MI/R injury via AMPactivated protein kinase (AMPK)–dependent metabolic regulation and AMPK-independent antioxidative/
antinitrative pathways. Compared to ND, HD mice manifested significantly blunted gAPN-induced AMPK
activation, basally and after MI/R ( p < 0.05). Although both low- and high-dose gAPN equally attenuated MI/
R-induced oxidative stress (i.e., NADPH oxidase expression and superoxide production) and nitrative stress (i.e.,
inducible nitric oxide synthase expression, nitric oxide production, and peroxynitrite formation) in ND mice,
only high-dose gAPN efficaciously did so in HD mice. We demonstrate for the first time that HD-induced
diabetes diminished both AMPK-dependent and AMPK-independent APN cardioprotection, suggesting an
unreported diabetic heart APN resistance. Antioxid. Redox Signal. 15, 1779–1788.

Introduction

I

schemic cardiovascular disease is a major cause of
morbidity and mortality in diabetic patients, who demonstrate enhanced vulnerability to ischemia/reperfusion insult
and resultant death. Clarification of the molecular link between type-2 diabetes and cardiovascular injury may therefore help identify novel efficacious therapies attenuating
postischemic myocardial injury, reducing myocardial ischemic morbidity, and ultimately decreasing diabetic mortality
of cardiovascular etiology.
Adiponectin (APN) is an adipocytokine secreted from adipose tissue (11). Numerous epidemiological studies have
demonstrated the correlation between reduced APN levels
and increased risk of cardiovascular disease in obese and diabetic individuals (1, 19). APN deficiency is an independent

risk factor for endothelial dysfunction, hypertension,
coronary heart disease, myocardial infarction, and other
cardiovascular complications (13). We and others have demonstrated through investigations that exogenous APN supplementation exerts significant cardiovascular protection
against myocardial ischemia/reperfusion (MI/R) injury.
However, to date, all studies reporting cardiovascular protection by APN were performed in nondiabetic animals (24,
25). Whether the cardioprotective actions of APN might be
altered in the diabetic state, a pathologic condition where
endogenous APN is significantly reduced and supplementation of APN may be most appropriate, has never been previously investigated.
Emerging evidence suggests that APN malfunction occurs
in the early stage of metabolic syndrome and contributes to
the development of insulin resistance, a pathologic condition
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known to play a key role in the etiology of diabetes mellitus
and related disorders. Specifically, there is reduced APNinduced AMP-activated protein kinase (AMPK) activation
in hepatic tissue from hypertensive or insulin receptor transgenic knockout animals; impaired APN stimulation of
AMPK/acetyl-CoA carboxylase (ACC) and fatty acid oxidation in cultured myotubes and skeletal muscle strips isolated
from obese/diabetic individuals has been documented (5, 7,
18, 21). High-fat diet (HD)–fed rats manifest loss of APNinduced acute ACC phosphorylation and stimulation of fatty
acid oxidation in their muscle, and this APN resistance precedes skeletal muscle lipid accumulation and insulin resistance (17). Further, our most recent studies demonstrated that
diet-induced obesity/hyperlipidemia caused significant vascular APN resistance (via AMPK/ACC phosphorylation and
endothelial nitric oxide synthase [eNOS] activation) (16).
However, whether and how diabetes may cause cardiac APN
resistance, thus diminishing the cardioprotective effects of
APN, has never been previously investigated.
Therefore, the aims of the present study were to determine
whether the cardioprotective effect of globular domain of
APN (gAPN) [the isoform with 20 times higher biologic activity than full length of APN (11)] against MI/R injury is
altered in a HD induced diabetic model, and if so, to identify
the potential underlying mechanisms for any observed altered APN function during in vivo MI/R in the diabetic state.

3 h (for all assays except cardiac function and infarct size) or
24 h (for cardiac function and infarct size only) reperfusion,
the ligature around the coronary artery was retied, and 1 ml of
2% Evans blue dye was injected into the left ventricular cavity.
The isolated Evans-blue-negative stained cardiac portion (ischemic/reperfused tissue, or area-at-risk) was utilized for
immunohistological, biochemical, and Western blot studies as
described below.

Materials and Methods

Quantification of superoxide production

Adult (6-week-old) male C57BL/6J mice were randomized
to receive a HD (60 kcal%) (Research Diets Inc. D12492i) or a
10 kcal% control normal diet (ND, D12450Bi) containing the
same protein content as the HD. All experiments were performed in adherence with the National Institutes of Health
Guidelines on the Use of Laboratory Animals, and were approved by the Thomas Jefferson University Committee on
Animal Care.

Myocardial superoxide content (in area-at-risk) was quantified by lucigenin-enhanced luminescence as described previously (25).

Metabolic characterization
Mice were fasted overnight by removal to a clean cage
without food at the end of their dark (feeding) cycle, *6 pm.
Mice were weighed the morning after at 8 am, and 30 ml blood
was obtained via tail clip to assess plasma glucose (Accu-Chek
Active Blood Glucose Monitoring System; Roche Diagnostics,
Indianapolis, IN), plasma insulin (enzyme-linked immunosorbent assay [ELISA]; Linco, Billerica, MA), and plasma APN
(ELISA; R&D Systems, Minneapolis, MN). Weight and plasma measurements were recorded initially and weekly thereafter. The Homeostatic Model Assessment (HOMA) score, a
surrogate measure of insulin resistance, was calculated initially and weekly thereafter, via HOMA calculator v2.2.2
(University of Oxford, United Kingdom).
After 8 weeks of being fed HD or ND, 14-week-old mice
were anesthetized with 2% isoflurane (total isoflurane exposure time < 5 min), and MI was produced via left anterior
descending coronary artery slip-knot ligation as described in
our previous studies (25). Twenty minutes after MI, both HD
mice and controls were randomized to one of the following
groups: sham MI (n = 12), MI + vehicle (n = 13), MI + low
dose gAPN (2 mg/g intraperitoneal injection IP; n = 13), and
MI + high dose gAPN (6 mg/g IP; n = 13). After 30 min of MI,
the slip-knot was released, and reperfusion commenced. After

Determination of myocardial apoptosis
and myocardial injury
Myocardial apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) staining, caspase-3 activity, and DNA fragmentation as described in our previous study (27). Serum levels of
the cardiac-specific isoform of troponin-I were determined
utilizing ELISA from Life Diagnostics (West Chester, PA) (8).
Myocardial infarct size was assessed by Evans blue—2,3,5triphenyl tetrazolium chloride double staining methods (27).
Determination of cardiac function
Cardiac function was determined by echocardiography
and left ventricular catheterization methods 24 h after reperfusion before thoracotomy, as described in our previous
studies (25, 27).

Determination of total nitric oxide and nitrotyrosine
content in cardiac tissue
The tissue nitric oxide (NO) and its metabolic products
(NO2 and NO3) were determined by use of a chemiluminescence NO detector (Siever 280i NO Analyzer), and MI/R
cardiac tissue nitrotyrosine (NT) content was quantified by
ELISA as described previously (25, 27).
Western blot analysis
Proteins were separated on sodium dodecyl sulfate–
polyacrylamide gel electrophoresis gels, transferred to nitrocellulose membranes, and incubated with primary antibodies
(monoclonal antibody against phosphorylated ACC, inducible NO synthase [iNOS] [Upstate, Chicago, IL], or gp91phox
[Transduction Laboratories, San Jose, CA]) and horseradish
peroxidase-conjugated secondary antibody. The blot was
developed with a Supersignal Chemiluminescence detection
kit (Pierce, Rockford, IL), and observed with a Kodak Image
Station 400 (Rochester, NY).
Statistical analysis
All values in the text and figures are presented as
mean – standard error of the mean of n independent experiments. Analysis of variance was performed across all investigated groups first. Post hoc pair-wise tests for certain group
pairs with assessment of statistical significance were then
performed after Bonferroni correction of the overall significance level. Western blot densities were analyzed with
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Kruskal–Wallis test followed by Dunn post hoc test. p-values
£ 0.05 were considered statistically significant. The authors
had full access to and take full responsibility for data integrity.
All authors have read and agreed to the article as written.
Results
Eight weeks HD induced type-2 diabetes in mice
We conducted initial experiments to determine the ability of
HD to induce type-2 diabetes in mice. Mice were fasted overnight, and body weight, plasma glucose, and insulin and APN
levels were determined (Fig. 1). HD-fed mice had greater body
weight increase than ND after 2 weeks (Fig. 1A, p < 0.01).
Concomitantly, fasting plasma glucose increased steadily in
HD mice after 2 weeks (Fig. 1B, p < 0.01), and fasting plasma
insulin increased from 6 weeks onward (Fig. 1C, p < 0.05).
After 5 weeks HD, calculated HOMA score was positively
correlated with elevating insulin levels (Fig. 1D, p < 0.01).
HD increased susceptibility to MI/R injury
HD mice had normal basal cardiac function (Sham MI/R
groups in Fig. 2). However, when subjected to in vivo MI/R
injury, HD mice manifested significantly greater cardiac injury than their ND controls. Specifically, MI/R-induced infarct size was enlarged (Fig. 2A), and cardiac function was
further depressed (Fig. 2B).
Cardioprotective effect of gAPN was attenuated
in HD mice
Having demonstrated that HD increased susceptibility to
MI/R injury, we compared the cardioprotective effect of
gAPN in HD and ND animals subjected to MI/R. Consistent
with our previously published finding, treatment of ND ani-

FIG. 1. High-fat diet (HD)
for 8 weeks induced type-2
diabetes model in mice.
(A) Body weight. (B) Fasting
plasma glucose. (C) Fasting
plasma insulin determined
by enzyme-linked immunosorbent assay. (D) Fasting
Homeostatic Model Assessment (HOMA) score calculated by fasting plasma glucose
and insulin. n = 10–13 mice
per group. *p < 0.05, **p < 0.01
versus normal diet (ND) mice
at the same time point.
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mals with 2 mg/g gAPN 10 min before reperfusion significantly attenuated MI/R-induced injury, as evidenced by
infarct size reduction (Evans blue/2,3,5-triphenyl tetrazolium
chloride double staining, Fig. 3A), cardiac function improvement (dP/dtmax, Fig. 3B), and apoptosis decrease (TUNEL
staining, Fig. 3C; caspase-3 activity, Fig. 3D). However,
treatment of HD animals with the same dose of gAPN (i.e.,
2 mg/g) only attenuated a relatively small portion of MI/Rinduced injury (33.5% reduction of infarct size, 31.8% increase
of dP/dtmax, 31.0% reduction of TUNEL positive cells, and
28.9% reduction of caspase-3 activity, p-value all < 0.05 vs.
2 mg/g gAPN-treated ND animals), indicating that the cardioprotective actions of gAPN are reduced in HD-induced
type-2 diabetic condition. To obtain more evidence supporting a hypothesis that type-2 diabetes causes cardiac APN resistance, the cardioprotective effects of a higher dose of gAPN
(6 mg/g) were investigated. As summarized in Figure 3, administration of high-dose gAPN failed to further enhance its
cardioprotection in ND mice, suggesting that the cardioprotective effects of gAPN against MI/R injury was already saturated at 2 mg/g. However, in HD animals, high-dose gAPN
alleviated more MI/R-induced damage than low-dose gAPN
(1.59-fold decrease in infarct size, 1.75-fold increase in dP/
dtmax, 1.72-fold reduction in TUNEL-positive cells, and 2.59fold decrease in caspase-3 activity, p < 0.05 vs. 2 mg/g group).
These novel data suggest attenuated cardioprotective action
of gAPN in the HD condition, which can be overcome with
increased gAPN dosage.
HD impaired gAPN-induced AMPK/ACC activation
in cardiomyocytes, both basally and post-MI/R
APN delivers much of its metabolic-regulatory effect via
the AMPK-ACC signaling axis (28). Previous studies have
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FIG. 2. HD increased susceptibility of myocardial ischemia/reperfusion
(MI/R)
injury. (A) Myocardial infarction determined by Evans
blue/2,3,5-triphenyl tetrazolium chloride double staining.
(B) Left ventricular ejection
fraction (LVEF) determined by
echocardiography. (C) Left ventricular wall thickness (LVAW)
determined by echocardiography. n = 10–13 mice per group.
**p < 0.01 versus sham control
in the same diet group;
&p < 0.05, &&p < 0.01 between
the different diet groups with
the same treatment (i.e., sham
MI/R or MI/R + V). (To see
this illustration in color the
reader is referred to the web
version of this article at www
.liebertonline.com/ars).

demonstrated impairment in the ability of APN to stimulate
AMPK/ACC phosphorylation in skeletal myocytes, hepatocytes, and endothelial cells cultured in hyperglycemic/
hyperlipidemic conditions. In consistent fashion, we observed
a 1.6- and 2.0-fold increase in AMPK phosphorylation and
ACC phosphorylation, respectively, in ND hearts after either
dose of gAPN treatment (Fig. 4A, B, left panels). However,
low-dose gAPN was only partially effective in doing so
(phosphorylating cardiac AMPK 44.1% and ACC 54.9% of
high-dose gAPN), and a higher-dose gAPN (i.e., 6 mg/g) was
required to stimulated cardiac AMPK/ACC phosphorylation
to the same level in HD mice compared to ND animals.
We next determined whether HD impaired AMPK/ACC
activation following MI/R. A 1.39-fold and 1.65-fold increase
in AMPK and ACC phosphorylation, respectively, was observed in ND hearts post-MI/R. Both gAPN doses further
enhanced AMPK (low-dose: 1.27-fold increase and high-dose:
1.26-fold increase) and ACC (low-dose: 1.30-fold increase
and high-dose: 1.21-fold increase) phosphorylation modestly
(Fig. 5A, B, left panel). However, low-dose gAPN failed to
further activate cardiac AMPK/ACC phosphorylation in HD
mice. A tripled dose of gAPN was required to achieve significant AMPK/ACC phosphorylation comparable to that
induced by 2 mg/g in ND animals (Fig. 5A, B, right panel).
Impaired APN-mediated antioxidative protection
in HD mice signified cardiac resistance to APN
Recently, we reported that gAPN exerts its cardioprotective effects via AMPK-dependent metabolic regulation and
AMPK-independent antioxidative/antinitrative actions (25).
Having demonstrated that AMPK/ACC activation by gAPN
was significantly blunted in HD animals, we further investigated whether the antioxidant/antinitrative action of gAPN is
also altered, thus contributing to its diminished cardiopro-

tective effects in diabetic animals. Two series of experiments
were performed.
In the first series of experiments, we measured MI/Rinduced oxidative stress. As illustrated in Figure 6A, there
was no significant difference between superoxide overproduction in ND mice and HD mice at basal conditions. However, superoxide production was enhanced by MI/R injury in
HD mice ( p < 0.001 vs. ND MI/R heart). gAPN (either dose)
significantly inhibited MI/R-induced superoxide overproduction to similar levels seen in ND animals (low/high-dose
gAPN, respectively, reduced 55.3%/49.0% superoxide production in ND animals, Fig. 6A). However, although highdose gAPN attenuated superoxide overproduction in HD
mice to levels seen in ND animals (54.3% reduction of superoxide production, p < 0.01), low-dose gAPN reduced superoxide production by only 29.8% ( p < 0.01), a 55.1% loss of
efficacy compared to high-dose gAPN in reducing superoxide
overproduction in HD animals (Fig. 6A).
We further determined the molecular sources potentially
responsible for the impaired antioxidant actions of APN in the
HD heart. There was significantly increased MI/R-induced
overexpression of gp91phox in HD hearts compared to ND (Fig.
6B; lane 2 vs. lane 6, p < 0.05), consistent with enhanced cardiac
superoxide overproduction trends in HD mice (Fig. 6A).
Treatment of ND mice with gAPN (either dose) significantly
inhibited gp91phox expression. However, only high dose of
gAPN was effective in inhibiting gp91phox expression in HD
animals (Fig. 6B, right panel), although the absolute level of
gp91phox expression remained greater in high-dose gAPNtreated HD hearts than gAPN-treated ND hearts. Together
with the data presented in Figure 6A, these results demonstrated that MI/R-induced oxidative stress was increased in
HD mice, and gAPN’s antioxidant effect was impaired, requiring increased APN dosage to maintain antioxidant cardioprotective efficacy under diabetic conditions.
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FIG. 3. Cardioprotective effect of globular domain of adiponectin (gAPN) was attenuated in HD mice. (A) Myocardial
infarction determined by Evans blue/2,3,5-triphenyl tetrazolium chloride double staining. (B) Left ventricular pressure (dP/dt)
determined by hemodynamic measurements. (C) Cardiomyocyte apoptosis determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL). (D) Caspase-3 activity. n = 10–13 mice per group. **p < 0.01 versus sham control
in the same diet group; ##p < 0.01 versus vehicle-treated group in the same diet group; $p < 0.05, $$p < 0.01 versus low dose gAPNtreated animals in the same diet group; &p < 0.05, &&p < 0.01 between different diet groups with the same treatment; ns, no
significant difference between compared groups.

FIG. 4. Reduced APN stimulated AMP-activated protein kinase (AMPK)/acetyl-CoA carboxylase (ACC) activation
occurred in HD mice. (A) Effect of adiponectin treatment on AMPKa2 phosphorylation determined by representative
Western blots. (B) Effect of adiponectin treatment on ACC phosphorylation determined by representative Western blots.
n = 5–8 hearts per group. **p < 0.01 versus sham control in the same diet group; $p < 0.05, $$p < 0.01 versus low dose gAPNtreated animals in the same diet group; &p < 0.05 between different diet groups with the same treatment.
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FIG. 5. Cardiac adiponectin resistance to stimulate AMPK/ACC activation occurred upon MI/R injury in HD mice. (A)
Effect of adiponectin treatment on AMPKa2 phosphorylation determined by representative Western blots. (B) Effect of
adiponectin treatment on ACC phosphorylation determined by representative Western blots. n = 5–8 hearts per group.
*p < 0.05, **p < 0.01 versus sham control in the same diet group; #p < 0.05, ##p < 0.01 versus vehicle-treated group in the same
diet group; $p < 0.05, $$p < 0.01 versus low dose gAPN-treated animals in the same diet group.

Impaired APN-mediated antinitrative protection in HD
mice further demonstrated cardiac resistance to APN
In the second series of experiments, we assessed MI/
R-induced myocardial nitrative stress. As illustrated in
Figure 7A, no significant difference was seen between total
NO content in ND and HD mice at basal conditions, but NO
production was further enhanced by MI/R injury in HD mice
( p < 0.01 vs. ND MI/R heart). gAPN (either dose) significantly inhibited MI/R-induced NO overproduction in ND
heart (low/high-gAPN dose reduced 42.7%/36.8%, respectively, NO overproduction, p < 0.01). In HD animals, highdose gAPN reversed NO overproduction to similar levels
seen in ND animals (47.1% reduction of NO overproduction,

p < 0.01), but low-dose gAPN reduced NO overproduction by
only 30.4% ( p < 0.01), a 35.5% loss of efficacy compared to
high-dose gAPN in decreasing NO overproduction in HD
animals (Fig. 7A).
Next, we determined the molecular sources potentially
responsible for the impaired antinitrative function of APN
observed in the HD condition. MI/R-induced overexpression
of iNOS was significantly increased in HD compared to ND
hearts (Fig. 7B; lane 2 vs. lane 6, p < 0.05). These data are
consistent with results in Figure 7A, showing that MI/Rinduced cardiac NO overproduction was further enhanced in
HD mice. Treatment of ND mice with gAPN (either dose)
significantly inhibited iNOS expression (Fig. 7B; low/highgAPN dose reduced 34.3%/36.3%, respectively, iNOS

FIG. 6. Cardiac adiponectin resistance in HD mice impaired its antioxidative protection. (A) Production of superoxide
(n = 8–10 hearts per group). (B) gp91phox determined by representative Western blots (n = 5–8 hearts per group). **p < 0.01
versus sham control in the same diet group; ##p < 0.01 versus vehicle-treated group in the same diet group; $$p < 0.01
versus low dose gAPN-treated animals in the same diet group; &&p < 0.01 between different diet groups with the same
treatment.
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FIG. 7. Cardiac adiponectin resistance impaired antinitrative protection. (A) Production of NOx content (n = 10–13 hearts
per group). (B) Inducible nitric oxide synthase (iNOS) expression (n = 5–7/group) by representative Western blots. **p < 0.01
versus sham control in the same diet group; ##p < 0.01 versus vehicle-treated group in the same diet group; $p < 0.05 versus low
dose gAPN-treated animals in the same diet group; &&p < 0.01 between different diet groups with the same treatment.

expression compared to vehicle, p < 0.01). Treatment of HD
mice with high-dose gAPN similarly inhibited iNOS expression (Fig. 7B; high-gAPN dose reduced 36.3% iNOS expression
compared to vehicle, p < 0.01). However, low-dose gAPN reduced iNOS expression only 13.8% compared to vehicle in HD
mice ( p < 0.01 vs. high dose). Together with the data presented
in Figure 7A, these results demonstrated that MI/R-induced
nitrative stress was increased in HD mice, and gAPN’s antinitrative effect was impaired, requiring increased APN dosage
to maintain antinitrative cardioprotective efficacy.
Currently, it is generally accepted that the conversion of the
cytoprotective molecule NO to a cytotoxic molecule, peroxynitrite, is the major mechanism responsible for superoxide
toxicity. As illustrated in Figure 8, NT content, the footprint of
peroxynitrite production, was increased by MI/R injury in
ND mice ( p < 0.01 vs. ND MI/R heart). gAPN (either dose)
significantly inhibited MI/R-induced NT generation in ND
heart (low/high-dose reduced 42.8%/36.7%, respectively, of
NT generation in ND heart). Whereas high-dose gAPN attenuated NT production in HD mice to levels seen in ND
littermates (47.2% reduction of NT production), low-dose
gAPN decreased NT production in HD animals only 20.4%, a
56.7% loss of efficacy compared to high-dose gAPN in decreasing NT overproduction in HD animals (Fig. 8).
Discussion
Several important observations have been made in the
present study. First, our results demonstrated that 8-week HDinduced diabetes diminished, but did not fully abrogate the
cardioprotective action of gAPN in a clinically relevant animal
model of in vivo regional MI/R. gAPN doses > 2 mg/g body
weight offered no additional cardioprotective benefit against
MI/R injury in ND mice, but this dose only reversed a minimal
portion of ischemia-induced myocardial apoptosis, infarct size,
and cardiac dysfunction in HD mice. This finding provides the
first evidence that a resistance to the cardioprotective effects of
APN develops in the diabetic condition in vivo. Second, we
have provided the first direct mechanistic evidence underlying

FIG. 8. Peroxynitrite was significantly blunted in HDinduced diabetic heart. (A) Nitrotyrosine content determined by ELISA (n = 10–13/group). **p < 0.01 versus
sham control in the same diet group; #p < 0.05, ##p < 0.01
versus vehicle-treated group in the same group; $$p < 0.01
versus low dose gAPN-treated animals in the same diet
group. (B) A schematic illustration of the hypothesis tested in
the current study. (To see this illustration in color the reader
is referred to the web version of this article at www
.liebertonline.com/ars).
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this impaired response to APN cardioprotection, which is
partly via AMPK-ACC activation resistance as well as diminished AMPK-independent antioxidative/antinitrative protection. Finally, we have demonstrated that, although APN
resistance impaired its cardioprotection, increased gAPN dosage can still attenuate MI/R-induced myocardial apoptosis,
reduce infarct size, and salvage cardiac function in the diabetic
condition, suggestive of a cautiously positive future clinical
application of APN.
APN is an abundant circulating adipocytokine secreted
from adipose tissue, which has at least three major functions,
including an insulin sensitization/metabolic-regulatory
function (in the liver and muscle), an anti-inflammatory/
vascular protective function, and an anti-ischemic/cardioprotective function. Numerous epidemiological studies reveal
the correlation between reduced APN levels and increased
morbidity/mortality of cardiovascular ischemic diseases and
diabetes mellitus (3, 10, 12, 15, 22, 29). Conversely, a higher
plasma APN concentration is associated with a lower risk of
ischemic heart disease in men (9, 15, 20). Moreover, Walsh’s
group (24) and our group (25) have recently demonstrated
markedly increased MI/R injury in APN-knockout mice, and
exogenous APN supplementation can significantly decrease
myocardial apoptosis, infarct size, and impaired cardiac
function. Together, these exciting results support the role of
APN as a directly cardioprotective molecule against MI/R
injury, suggesting that APN might be a novel therapeutic
molecule in the treatment of diabetic cardiovascular injury.
In obesity and type-2 diabetes, tissue response to insulin is
significantly blunted, and this insulin resistance is known to
play a key role in the pathogenesis of diabetes mellitus and
related disorders (26). Numerous studies have demonstrated
that APN shares many biological functions with insulin, including lipid oxidation, glucose uptake, and cardiovascular
protection, and that there exists APN and insulin signaling
cross-talk at multiple levels (4). However, whether obesity
and type-2 diabetes may also alter tissue response to APN has
just begun to be recognized and the potential impact of APN
resistance on diabetic cardiovascular injury remains largely
unknown. Specifically, although the anti-ischemic/cardioprotective effects of APN have been well-recognized, there
has been no investigation regarding the cardioprotective effects of APN in the obesity/diabetic animal, a pathologic
condition where supplementation of APN is needed. Here, we
demonstrate that a HD-induced diabetic model attenuates the
cardioprotective actions of gAPN in response to regional MI/
R in vivo, providing the first direct evidence of cardiac resistance to APN.
The majority of APN’s metabolic regulatory function occurs via the AMPK/ACC signaling axis (28), whereas its inhibition of the inflammatory response and elicitation of
vasodilatation/vasculoprotection occurs largely through the
AMPK/eNOS axis (6, 23). Consistent with these studies, our
present data demonstrated gAPN further activated AMPK
and phosphorylated ACC downstream, effecting cardioprotection against MI/R injury in ND mice. Importantly, HD
weakened this AMPK-ACC phosphorylation and impaired
cardioprotection of gAPN, giving novel mechanistic evidence
that observed APN resistance in cardioprotection occurs
partly via impaired AMPK activation.
Although the AMPK pathway is critical to APN’s metabolic-regulatory, anti-inflammatory, and vasculoprotective
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function, we have recently provided direct evidence of
AMPK-independent gAPN-mediated cardioprotection in the
intact animal (27). Overproduction of reactive oxygen species
is a central cause of reperfusion-induced endoplasmic reticulum stress and apoptosis, and we recently demonstrated that
APN inhibited gp91phox (the essential membrane component
of NADPH oxidase responsible for a large portion of superoxide production in the MI/R heart) overexpression, thus attenuating oxidative stress-induced tissue injury (25). Presently,
we demonstrate increased gp91phox expression and enhanced
superoxide production in diabetic hearts. Although gAPN
significantly reversed MI/R-induced gp91phox over-expression
and superoxide overproduction in ND mice, the same gAPN
dose could only attenuate a small percentage of MI/R-induced
oxidative stress, and a tripled gAPN dose was required to halt
MI/R-induced superoxide generation and diminish gp91phox
overexpression in HD mice to levels observed in ND littermates. Together, these results show impairment of gAPN’s
antioxidant effect, and increased APN dosage is required to
sustain its antioxidant cardioprotective efficacy.
APN is known to stimulate NO production via AMPKmediated eNOS phosphorylation. However, both iNOS expression and total NO production are markedly enhanced in
IR tissue from APN-KO mice (25). By itself, NO is not toxic
and does not cause significant tissue injury, even at very
high concentration in physiological conditions (14). However,
in the presence of O2 - (which occurs during ischemia/
reperfusion) NO reacts to form peroxynitrite, an extremely
toxic molecule causative of rampant oxidative/nitrative
tissue injury (2, 25). We previously demonstrated the antinitrative effects of gAPN in MI/R hearts are not AMPKmediated (27). Presently, we show that the diabetic state
unfettered gAPN’s inhibition of iNOS overexpression, thus
increasing NO production and peroxynitrite formation.
However, gAPN’s antinitrative properties could be regained
with increased gAPN dosage.
Collectively, our data demonstrated that diabetes blunted
gAPN cardioprotection by impairing both AMPK-dependent
and AMPK-independent pathways through which gAPN
protects ischemic/reperfused heart. These results further indicate that the APN resistance is developed at high levels
before the divergence of gAPN cardioprotective signaling.
The detailed mechanisms underlying how the diabetic condition impairs the cardiomyocyte response to APN concerning activation of AMPK and antioxidative/nitrative effect is
currently under investigation. Moreover, the cardioprotection
of gAPN was blunted but no abrogated, and a higher concentration remains to be effective in diabetic animals. These
results may potentially translate to differential clinical treatment plans for diabetic versus nondiabetic patients in the face
of myocardial ischemic injury.
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ACC ¼ acetyl-CoA carboxylase
AMPK ¼ AMP-activated protein kinase
APN ¼ adiponectin
ELISA ¼ enzyme-linked immunosorbent assay
eNOS ¼ endothelial nitric oxide synthase
gAPN ¼ globular domain of adiponectin
HD ¼ high-fat diet
HOMA ¼ Homeostatic Model Assessment
LVAW ¼ left ventricular wall thickness
LVEF ¼ left ventricular ejection fraction
MI/R ¼ myocardial ischemia/reperfusion
ND ¼ normal diet
NO ¼ nitric oxide
NT ¼ nitrotyrosine
TUNEL ¼ terminal deoxynucleotidyl transferase–
mediated dUTP nick-end labeling
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